Anti-dsDNA Calculator: Assesses antibody levels to evaluate systemic lupus erythematosus activity.
IU/mL
Enter Anti-dsDNA Level
Enter the anti-dsDNA level in IU/mL to interpret the antibody result.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Diagnostic workup for suspected systemic lupus erythematosus
Monitoring SLE disease activity, particularly renal involvement
Predicting and detecting lupus flares before clinical symptoms appear
Part of the ACR 1997 and SLICC 2012 classification criteria for SLE
Assessing treatment response in patients with active lupus nephritis
Patient Population
Adults and children with suspected or confirmed SLE. Anti-dsDNA is one of the most specific laboratory tests for SLE, with specificity exceeding 95% when measured by validated methods such as the Farr assay or Crithidia luciliae immunofluorescence (CLIFT).
Interpretative Context
Anti-dsDNA antibodies are present in approximately 50–80% of SLE patients depending on the assay method and population studied. A positive anti-dsDNA in the appropriate clinical context strongly supports a diagnosis of SLE, but a negative result does not exclude it.
How it Works
Pathophysiology
Anti-dsDNA antibodies target double-stranded DNA, a key component of the cell nucleus. They are considered pathogenic because they can form immune complexes that deposit in tissues, particularly the glomerular basement membrane of the kidney, triggering complement activation and inflammatory damage. Anti-dsDNA antibodies of the IgG isotype are most strongly associated with disease activity and nephritis. Rising titres often precede clinical flares by several weeks to months.
Assay Methods
| Method | Principle | Sensitivity/Specificity | Notes |
|---|---|---|---|
| Farr assay | Radioimmunoassay using ammonium sulphate precipitation | High sensitivity, high specificity | Gold standard; detects high-avidity antibodies; requires radioactive materials |
| ELISA | Anti-dsDNA captured on plate, detected by enzyme-labelled anti-IgG | High sensitivity, moderate specificity | Most common method; may detect low-avidity antibodies of less clinical significance |
| CLIFT (Crithidia luciliae) | Immunofluorescence on Crithidia luciliae kinetoplast | Moderate sensitivity, very high specificity | Highly specific; detects only high-avidity antibodies; semi-quantitative |
| Multiplex bead assay | Luminex-based detection of anti-dsDNA on beads | Variable | Emerging technology; may have lower specificity than Farr |
Antibody Characteristics
High-avidity, complement-fixing IgG anti-dsDNA antibodies are the most pathogenic. The Farr assay and CLIFT preferentially detect these high-avidity antibodies and therefore correlate better with disease activity, especially lupus nephritis. ELISA methods may detect both high- and low-avidity antibodies, which can lead to positive results that are less clinically significant.
Clinical Pearls
Clinical Application
Serial anti-dsDNA monitoring is a cornerstone of SLE management. A rising titre should prompt closer clinical surveillance for impending flare, particularly in patients with known renal disease. The combination of rising anti-dsDNA and falling complement (C3, C4) is a powerful predictor of lupus flare, especially nephritis. In clinical trials, anti-dsDNA levels are used as both an entry criterion and a pharmacodynamic biomarker of treatment response.
Pitfalls to Avoid
Not all anti-dsDNA assays are equal; use the same method consistently for serial monitoring
Low-positive ELISA results may have limited clinical significance; confirm with a high-specificity method
Anti-dsDNA can be transiently positive during infections in patients without SLE
Titres do not always correlate perfectly with disease activity; clinical correlation is essential
Some SLE patients are persistently anti-dsDNA-negative; this does not rule out active lupus
Anti-dsDNA is less commonly positive in drug-induced lupus (typically anti-histone positive instead)
Complement Connection
Anti-dsDNA and complement levels should be interpreted together. Rising anti-dsDNA + falling C3/C4 = high risk of flare. Falling anti-dsDNA + normalising complement = treatment response. This pattern is particularly important in lupus nephritis monitoring.
Next Steps
Anti-dsDNA Positive
01
Assess for clinical features of SLE using ACR or SLICC classification criteria
02
Check complement levels (C3, C4) to assess immune complex activity
03
Evaluate renal function: urinalysis, protein-to-creatinine ratio, serum creatinine
04
If nephritis is suspected, consider renal biopsy for histologic classification
05
Monitor titre and complement every 1–3 months during active disease
06
Initiate or escalate immunosuppression if rising titre coincides with clinical activity
Anti-dsDNA Negative with High Clinical Suspicion
01
Test for other autoantibodies: ANA, anti-Sm, anti-Ro/SSA, anti-La/SSB, anti-RNP
02
Consider that anti-dsDNA may be absent in 20–50% of SLE patients
03
Repeat anti-dsDNA testing by a different method (e.g., Farr if ELISA was negative)
04
Proceed with clinical diagnosis if other criteria are met
05
Monitor for future seroconversion, which may occur during disease flares
Disease Activity Scores Using Anti-dsDNA
SLEDAI-2K (scores increased DNA binding)
BILAG-2004 (immunology domain)
Lupus Activity Index (anti-dsDNA component)
The Evidence
Key Evidence
Anti-dsDNA has specificity > 95% for SLE when measured by Farr assay or CLIFT
Rising anti-dsDNA titres precede clinical flares by 8–10 weeks in prospective studies
Patients with high-avidity anti-dsDNA have a 5-fold increased risk of lupus nephritis
The combination of rising anti-dsDNA and falling C3/C4 is the strongest serologic predictor of flare
Anti-dsDNA levels correlate with histologic activity class in lupus nephritis biopsies
Primary Reference
Are anti-double-stranded DNA antibodies a better marker than other autoantibodies for the diagnosis of systemic lupus erythematosus?
Bizzaro N et al. • Autoimmunity Reviews. 2018;17(3):261-9
Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study.
ter Borg EJ et al. • Arthritis and Rheumatism. 1990;33(5):634-43
Origins & History
Historical Context
Anti-dsDNA antibodies were first described in the 1950s alongside the discovery of the lupus erythematosus (LE) cell phenomenon. The Farr assay, developed in 1958 by Robert Farr, became the gold standard for detection. The discovery that anti-dsDNA specifically targets native (double-stranded) DNA rather than single-stranded DNA was critical, as antibodies to ssDNA are less specific for SLE and can occur in many conditions. The pathogenicity of anti-dsDNA was definitively established through renal elution studies showing concentrated anti-dsDNA in glomeruli of patients with lupus nephritis.
Last Comprehensive Review: 2026-07-17